Which glioblastoma patients will respond to immunotherapy? New biomarker discovery could prolong lives of estimated 20% to 30% of these malignant brain tumor patients — ScienceDaily
Northwestern Medicine scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas — the most common and malignant of primary brain tumors — might benefit…
